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1
osting by EAbstract A review with 75 references is presented that deals with the reported methods for analysis
of some important central nervous system (CNS) drugs in biological ﬂuids utilizing stir bar sorptive
extraction (SBSE) technique covering the years from 2000 to 2008. The theoretical aspects of SBSE,
as well as an signiﬁcant number of applications have been published, showing the advantages of this
technique over the classical extraction techniques (liquid–liquid extraction (LLE) and solid-phase
extraction (SFE). In this review, recent SBSE developments and a focus on the development of
new instrumental approaches and sorbent phases are presented.
ª 2010 King Saud University. All rights reserved.1. Introduction
Most common techniques for extraction drugs from biological
ﬂuids have been liquid–liquid extraction (Vlase et al., 2005;
Malfara´ et al., 2007; Titier et al., 2003) and solid-phase extrac-
tion (Juan et al., 2005; Sabbiono et al., 2004; Frahnert et al.,
2003). However, modern trends in analytical chemistry are to-
wards the simpliﬁcation, in miniaturization of sample prepara-
tion, minimization of sample preparation, minimization of
organic solvent used and sample volumes. In particular the
reduction of solvent consumption in analytical laboratories isity. All rights reserved. Peer-
d University.
lsevierexpected to contribute signiﬁcantly to reduction of analytical
costs (Melo et al., 2009).
New solventless sample-enrichment techniques that allow
direct extraction of solutes from biological ﬂuids have recently
been introduced such as stir bar sorptive extraction (SBSE)
(Tienpont et al., 2002; Benijts et al., 2001; Fernandes et al.,
2006; Tiepont et al., 2003; Kawaguchi et al., 2004a,b; Lambert
et al., 2005; Chaves et al., 2007), solid-phase microextraction
(SPME) (Silva et al., 2007; Alves et al., 2007) and in tube
SPME (Silva et al., 2008; Queiroz et al., 2007). The techniques
combine extraction and concentration of analytes in a single
step, thereby reducing the time required to prepare the sam-
ples. In SBSE, a stir bar coated with polydimethylsiloxane
(PDMS) phase is added to a vial containing the sample as
shown in Fig. 1; this is stirred until analytes partition equilib-
rium time reached with sorbent. After the extraction, the ana-
lytes can be introduced quantitatively into the analytical
system by thermal or liquid desorption (Tienpont et al., 2002).
The PDMS (non-polar phase) is the only commercially
available polymer for coating stir bars. More recently, in-
house procedures for stir bar coating have been developed to
Figure 1 Schematicatic of SBSE set-up.
26 M.G. Kassemincrease the versatility of SBSE technique. Bicchi et al. (2005)
developed dual-phase twisters using different carbons as an
additional concentrating phase. The successful combination
of two concentrating phases enhanced the recovery of volatile
and/or polar compounds compared with conventional PDMS
stir bars. Liu et al. (2004) described the use of a compact and
thermally stable porous hydroxy-terminated phase for the
extraction of polycyclic aromatic hydrocarbons, n-alkanes,
and phosphorus pesticides from water samples.
Lambert et al. (2005) prepared a biocompatible stir bar
sorptive extraction device using an alkyl-diol-silica (ADS) re-
stricted access material (RAM) as the SBSE coating. The
ADS-RAM SBSE was able to simultaneously fractionate the
protein component from a biological sample, while directly
extracting caffeine and its metabolites, overcoming the present
disadvantages of direct sampling in biological matrices, such as
fouling of the extracting coating by proteins. Nogueira and
Silva (Silva and Nogueira, 2008) proposed polyurethane foams
as new polymeric phases for SBSE. It was demonstrated that
these polymers present remarkable stability and excellent
mechanical resistance for the enrichment of organic com-
pounds from aqueous samples. Huang et al. (2008) developed
a monolithic new phase, poly(methacrylic acid stearyl ester-
ethylene dimethacrylate), for simultaneous SBSE/LC determi-
nation of six steroid sex hormones in urine.
Polypyrrole has been used as an extraction phase due to its
permeability (porous structure), and multifunctional proper-
ties, which result in intermolecular interactions like acid-base,
p-p, dipole-dipole, hydrophobic hydrogen bonding, and ion
exchange between the polymer and analyte (Wu and Paw-
liszyn, 2001; Pawliszyn and Wu, 2001).
A new polymeric coating consisting of a dual-phase dimeth-
ylsiloxane (PDMS) and polypyrrole (PPY) was developed for
stir bar sorptive extraction (SBSE) of second generation anti-
depressants from plasma samples for therapeutic drug moni-
toring (Melo et al., 2009). In this review article the author
focused on the novel methods that involve SBSE and their
applications in CNS drugs analysis.
2. Stir bar sorptive extraction (SBSE) principle
Sorptive extraction by nature is an equilibrium technique, and
for a water samples the extraction of solutes from aqueousphase into the extraction medium is controlled by the parti-
tioning coefﬁcient of the solutes between the silicone phase
and the aqueous phase (Lord and Pawliszyn, 2000). Studies
have correlated this partitioning coefﬁcient with the octanol–
water distribution coefﬁcients (Ko/w). Although not fully cor-
rect, the octanol–water distribution coefﬁcient gives a good
indication if and how well a given solute can be extracted with
solid-phase micro-extraction (SPME) or stir bar sorptive
extraction (Baltussen et al., 1999a,b; Pasche and Popp, 1999).
Moreover, it is very important to realize that the sorption
equilibrium is also depend upon the phase ratio, and thus on
the amount of polydimethylsiloxane applied. This relationship
is shown in Eq. (1).
Ko=w ¼ KPDMS=w ¼ CPDMS
CW
¼ mPDMS
mw
 Vw
VPDMS
¼ mPMDS
mw
b ð1Þ
The distribution coefﬁcient between polydimethylsiloxane
and water (KPDMS/w) is deﬁned as the ratio between the con-
centration of a solute in the polydimethylsiloxane phase
(CPDMS) over the concentration in the water (Cw) at equilib-
rium. This ratio is equal to the ratio of the mass of the solute
in the polydimethylsiloxane phase (mPDMS) over the mass of
the solute in the aqueous phase (mw) times the phase ratio b
(with b= Vw/VPDMS).
The recovery, expressed as the ratio of the extracted
amount of solute (mPDMS) over the original amount of solute
in the water (mo = mPDMS + mw) thus is determined by the
distribution coefﬁcient KPDMS/w and by the phase ratio b, as
described in Eq. (2):
mPDMS
mo
¼ KPMDS=W=b
1þ ðKPDMS=w=bÞ ð2Þ
Using this equation, the theoretical recovery for a solute
with a known partition coefﬁcient and a given phase ratio
can be calculated. The obtained value, however, is only ob-
tained under full equilibrium conditions. From Eq. (2), it is
clear that the extraction efﬁciency increases with increasing
KPDMS/w. Since KPDMS/w is similar to the octanol–water distri-
bution coefﬁcient (Ko/w), extraction efﬁciency on PDMS, in
general, decreases with increasing polarity. Besides the
KPDMS/w factor, the phase ratio b (volume sample/volume
polydimethylsiloxane) also is important. The higher the
dimethylsiloxane concentration, the lower the b factor and
higher the extraction efﬁciency.
Fig. 2 shows the inﬂuence of Ko/w and phase ratio on
extraction efﬁciency. For a given phase ratio (sample vol-
ume/PDMS volume) an ‘‘S-shape’’ curve is obtained, whereby
the position of the curve depends on the b ratio (David et al.,
2003). For SPME, the volume of polydimethylsiloxane is
0.5 lL. For a sample of 10 mL, the phase ratio is thus
20,000. This results in poor recoveries for solutes with low
Ko/w values. A solute with log Ko/w = 3 (e.g. naphthalene,
Ko/w = 3.17) is only recovered for 4.8%.
Using SBSE with a 1 cm stir bar coated with 0.5 mm phase
(ﬁlm-thickness df = 0.5 mm), the PDMS volume is 25 lL the b
ratio 417 (also for a 10 ml sample volume). For a solute with
Ko/w = 3, the recovery increases to 71%. From Fig. 2, it is
clear that in SBSE quantitative extraction (100%) is reached
at much lower Ko/w values than in SPME. The increased recov-
ery obtained by SBSE in comparison to SPME has been dem-
onstrated by different groups using pesticides (Popp et al.,
2003; Blasco et al., 2004) as test solutes. Also, in headspace
Figure 2 Theoretical recovery (%) in function of solute log Ko/w
for SPME (100 lm ﬁber, 0.5 lL PDMS) and SBSE (1 cm ·
0.5 mm df, 25 lL PDMS) and 10 mL sample volume. Equilibrium
sampling is assumed.
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in comparison to SPME, as demonstrated by Tienpont et al.
(2000).
If the experimental recoveries obtained for a mixture of vol-
atile organic compounds are plotted versus the octanol–water
partitioning coefﬁcient of the solutes, an ‘‘S-shape’’ curve is
obtained showing good correlation between experimental
and theoretical values. The theoretical recoveries (at equilib-
rium) can thus calculated for a given sample volume selected
stir bar dimensions, and a solute using the Ko/w WIN Software
Program (Syracuse Research Corp., Syracuse, New York),
which is based upon a log Ko/w calculator.
For trace analysis, not only the theoretical recovery is
important, but also the enrichment factor and the total abso-
lute amount that can be introduced in the analytical system
(GC or LC) and detector. This amount can be predicted from
the theoretical recovery and sample volume (Lord and
Pawliszyn, 2000).
In addition to these thermodynamics, controlling the
extraction under equilibrium conditions, the kinetic aspect is
also important. During extraction, the solute, should migrate
from the sample into PDMS coating. The uptake rate is con-
trolled by diffusion constant, stirring conditions, sample vol-
ume, etc. (Bicchi et al., 2003).
This relationship is quite complex, but it is clear that the
time needed to reach equilibrium drastically increases with
increasing sample volume and PDMS volume. The inﬂuence
of Ko/w, sample volume PDMS volume and extraction times
was studied by Bicchi et al. (2003), using three pesticides
(methyl-parathion, b-endosulfan and buprofezin) with log
Ko/w values of 2.87, 3.83 and 4.30, respectively. Three PDMS
volumes (20, 40 and 110 lL), sample volumes ranging from
4 mL to 1 L and extraction times from 40 min up to 24 h were
tested. Water samples were spiked at concentrations below
water solubility and constant solute amounts were used in dif-
ferent sample volumes in order to avoid PDMS overloading.
The results showed that for b values between 36 (4 mL sam-
ple/110 lL PDMS) and 500 (10 mL sample/20 lL PDMS)
good correlation between experimental and predicted recover-
ies were obtained using a 40 min extraction time. For b values
between 1000 and 5000 (100 mL sample/20, 40 and 110 lL
PDMS) deviations increased with increasing b value.This conﬁrms that the extraction mechanism is based on
sorption. For a 100 mL sample and smallest b value, equilibra-
tion was reached only after 6 h. Finally, for a 1 L sample, b va-
lue up to 50,000) up to 24 h is needed to reach equilibrium
depending on Ko/w. This study also demonstrated that the sam-
ple volume/PDMS volume can be optimized for a given appli-
cation taking into account a practically acceptable extraction
time (Bicchi et al., 2003). As in SPME, often non-equilibrium
conditions are used in practical SBSE using an appropriate
internal standard and calibrated condition, excellent quantiﬁ-
cation is possible.3. SBSE with derivatization
3.1. SBSE with in situ derivatization
In the biochemical/life science application area, special atten-
tion should be paid to the possibilities of in situ derivatization
combined with SBSE, since often the target compounds are
quite polar (e.g. metabolites) (David and Sandra, 2007).
Since the PDMS phase is a non-polar liquid phase, it is
preferable that the polarity of the analyte be low. Relatively
high polar compounds, such as phenolic compounds, are not
well recovered. Therefore, SBSE with in situ derivatization,
wherein derivatization and SBSE are performed at the same
time, was developed (Ochiai et al., 2003; Kawaguchi et al.,
2005, 2004c). The derivatization of a phenolic hydroxyl group
with acetic acid anhydride (Melo et al., 2009; Fernandes et al.,
2006; Kawaguchi et al., 2004a; Ochiai et al., 2003; Ito et al.,
2005), a carboxyl group with ethylchloroformate (Melo
et al., 2009; Fernandes et al., 2006; Ochiai et al., 2003), and
carbonyl compounds with O-(2,3,4,5,6-penta-ﬂuorobenzyl)
hydroxylamine (Ochiai et al., 2003) has been reported.
In addition, the determination of organotin in water sample
by SBSE with in situ derivatization using sodium tetrethylb-
orate has been reported (Vercauteren et al., 2001). As shown
in Eq. (2) when log Ko/w is increased, the theoretical recovery
is increased. Moreover, in the analysis by gas chromatography
(GC), decreasing the polarity leads to improved sensitivity. In
addition, the derivative of an analyte with high log Ko/w
reaches equilibrium rapidly, whereas the analyte with low
Ko/w reaches equilibrium slowly (Kawaguchi et al., 2004b,c,
2005). Therefore, SBSE with in situ derivatization can be
accomplished at a shorter time compared with conventional
SBSE.
3.2. Thermal desorption (TD) with in tube derivatization
Because of SBSE with in situ derivatization involves derivati-
zation in a water sample, the silylation agent that can deriva-
tize various functional group is limited (Kawaguchi et al.,
2006). Therefore, there is a limitation in the derivatization of
the functional groups. To solve this problem, TD with in tube
derivatization, in which the target compound is derivatized
during TD from the PDMS-coated stir bar, was developed
(Kawaguchi et al., 2005).
As a result for examining various silylation agents, N,O-bis
(trimethylsilyl)triﬂuoroacetamide (BSTFA) was chosen be-
cause of its high volatility, and TD with in tube derivatization
was achieved. Because BSTFA is able to derivatize various
functional groups, the application of TD with in tube
28 M.G. Kassemderivatization to the measurement of various analytes is ex-
pected. The outline of TD with in tube derivatization was re-
ported (Kawaguchi et al., 2004c, 2006).
4. SBSE with in situ deconjugation
Many compounds are metabolized into gluconic acid or sulfate
conjugate in the human body. In order to determine such com-
pounds in biological samples, SBSE is performed prior to
deconjugation (Ochiai et al., 2003; Kawaguchi et al., 2005,
2004c). However, the deconjugation process is tedious and
time-consuming. Recently, Kawaguchi and co-workers
(Kawaguchi et al., 2004c, 2006) developed SBSE with in situ
deconjugation, wherein SBSE and deconjugation are per-
formed at the same time as a result, the separation time was
successfully shortened.
The common protocol for SBSE with situ de-conjugation is
as follows: A biological sample, such as urine, or plasma, is
added to a vial. Since the enzymatic activity is susceptible toC
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Figure 3 Structure of some sepH, a suitable buffer solution is added. Then b-gluconidase
is added for the deconjugation. A PDMS-coated stir bar is
added and the sample is stirred for 30-240 min. After extrac-
tion, the stir bar is removed, and very gently wiped with lint-
free tissue to remove water droplets. Then, it is subjected to
TD-GC–MS.
5. SBSE application for CNS drugs analysis
5.1. SBSE/LC–UV analysis of antidepressants in plasma
samples
A new polymeric coating consisting of a dual-phase, poly-
dimethylsiloxane (PDMS) and polypyrrole (PPY) was devel-
oped by Melo et al. (2009) for stir bar sorptive extraction
(SBSE) of antidepressants (mirtazapine, citalopram, paroxe-
tine, duloxetne, ﬂuoxetine and sertraline) (Fig. 3) from plasma
samples, followed by liquid chromatography analysis (SBSE/
LC–UV). The extractions were based on both adsorptionN
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as extraction time, temperature, pH of the matrix and desorp-
tion time were optimized, in order to achieve suitable analyti-
cal sensitivity in a short time period.
The PDMS/PPY coated stir bar showed high extraction
efﬁciency (sensitivity and selectivity) toward the target ana-
lytes. The quantiﬁcation limits (LOQ) of the reported SBSE/
LC–UV method ranged from 20 to 50 ng/mL, and the linear
range was from LOQ to 500 ng/mL with a determination coef-
ﬁcient higher than 0.99. The inter-day precision of the SBSE/
LC-UV method presented a variation coefﬁcient lower than
15%. The efﬁciency of the SBSE/LC–UV method was proved
by the analysis of plasma samples from elderly depressed
patients.
On the bases of the data obtained (Table 1).
Melo et al. (2009) concluded that the best SBSE experimen-
tal conditions for the antidepressant assays were 1.0 mL plas-Figure 4 Chromatogram of the antidepressant (a) blank plasma s
mirtazapine, (2) citalopram, (3) paroxetine, (4) duloxetine, (5) ﬂuoxeti
Table 1 Linear regression, LOQ and LOD for SBSE/LC-UV meth
Antidepressants Linear regression (LOQ-500 ng/mL)
Mirtazapine y= 0.109 + 0.0014x
Citalopram y= 0.0183 + 0.0013x
Paroxetine y= 0.0473 + 5.37 · 104x
Duloxetine y= 0.1205 + 0.0023x
Fluoxetine y= 0.0241 + 0.0022x
Sertraline y= 0.1192 + 9.12 · 104x
a LOQ, quantiﬁcation limit.
b LOD, detection limit.ma sample modiﬁed with 4 mL borate buffer (pH 9.0);
extraction temperature of 40 C, stirring for 40 min followed
by the drug liquid desorption by immersion of the PDMS/
PPY stir bar on 200 lL of mobile phase at a temperature at
25 C, under sonication for 15 min. The selectivity of the re-
ported method (Melo et al., 2009) is demonstrated by represen-
tative chromatograms of a drug-free human plasma sample,
and a drug-free human plasma spiked with antidepressants
at the therapeutic concentration (Fig. 4).
The commercial stir bar Twister for sorptive extraction was
used by Chaves et al. (2007) for extraction and determination
of sertraline, mirtazapine, ﬂuoxetine, citalopram, paroxetine,
imipramine, nortriptyline, amitriptyne and desipramine
(Fig. 3) in plasma after oral administration of these antidepres-
sants by (SBSE/LC–UV) method. Important factors in the
optimization of SBSE efﬁciency were discussed, such as extrac-
tion time, pH, ionic strength, inﬂuence of plasma proteins andpiked with antidepressants at a concentration of 500 ng/mL (1)
ne, (6) sertraline, (7) clomipramine; (b) blank plasma sample.
od for antidepressant drugs (n= 5).
r2 LOQa (ng/mL) LODb (ng/mL)
0.9935 20.0 5.0
0.9974 20.0 5.0
0.9942 30.0 10.0
0.9947 20.0 5.0
0.9980 30.0 10.0
0.9981 50.0 20.0
30 M.G. Kassemdesorption conditions: solvents, modes (magnetic stir, ultra-
sonic), time and desorption steps. The SBSE/LC-UV method
(Table 2) showed to be linear in a concentration ranging from
the limit of quantiﬁcation (LOQ) to 1000.0 ng/mL. The LOQ
values ranged from 10.0 to 40.0 ng/mL.
The inter-day precision of the reported SBSE/LC-UV
method (Melo et al., 2009) presented coefﬁcient of the varia-
tion lower than 15%. Based on ﬁgures of the merit results,
the SBSE/LC–UV methodology showed to be adequate to
the antidepressants analyses from therapeutic to toxic thera-
peutic levels. In order to evaluate the reported method for clin-
ical use, SBSE/LC–UV method was applied to analysis of
plasma samples from elderly depressed patients (Melo et al.,
2009).
The comparison between PDMS/PPY SBSE/LC-UV analy-
ses and commercial PDMS SBSE/LC-UV analyses was also
addressed (Melo et al., 2009; Chaves et al., 2007). The optimal
SBSE conditions for commercial PDMS phase were very sim-
ilar to conditions established for PDMS/PPY phase. Fig. 5
illustrates the comparison between the LC peak areas obtained
from PDMS/PPY and PDMS SBSE/LC analyses on plasma
spiked with antidepressants (500 ng/mL). As can be observedTable 2 Linearity and limit of quantiﬁcation (LOQ) of the
reported SBSE/LC method for antidepressant drugs.
Drugs Linear regression
(LOQ-1000 ng/mL)
r2 LOQa
(ng/mL)
Paroxetine y= 16693.58 + 1186.827x 0.9973 40.0
Citalopram y= 42655.79 + 1390.24x 0.9987 10.0
Mirtazapine y= 15432.48 + 1194.314x 0.9953 40.0
Fluoxetine y= 6343.09 + 1091.106x 0.9986 25.0
Sertraline y= 55986.42 + 411.72x 0.9960 35.0
Imipramine y= 39466.7 + 792.67x 0.9958 35.0
Amitriptyline y= 2089.3 + 8.9x 0.9975 15.0
Nortriptyline y= 1958.92 + 8.2x 0.9996 15.0
Desipramine y= 4886.56 + 7.69x 0.9965 35.0
a LOQ, quantiﬁcation limit.
Table 3 Methods previously published for the analysis of ﬂuoxetin
Sample preparation
technique
Solvent
consumption
on sample
preparation (mL)
Approximate analysis time (min)
Sample
preparation
Chromatography To
LLE 1.3 60 10 70
LLE 5.7 30 20 50
LLE 2.1 50 10 60
LLE 7.2 35 8 43
LLE 7.3 40 8 48
SPE 13.0 30 15 45
SPE 13.0 45 60 105
SPE 3.75 30 7 37
SPE 3.5 40 10 50
SPE 6.2 40 7 47
Column-switching 0 n.a. n.a. 5
Column-switching 0 n.a. n.a. 30
SPME 0 40 15 55
SPME 0.05 45 10 55
SBSE 0.09 45 7 52
n.a., not available.for the majority of the analytes, the PDMS/PPY phase pre-
sented LC peak areas higher than PDMS commercial phase.
5.2. SBSE/GC–MS determination of ﬂuoxetine in plasma
Stir bar sorptive extraction (SBSE) with in situ derivatization,
in combination with either thermal or liquid desorption on-line
coupled to gas chromatography–mass spectrometry was em-
ployed by Lanc¸as and co-workers Fernandes et al. (2007) for
the analysis of ﬂuoxetine in plasma samples. Ethylchlorofor-
mate was employed as derivatizing agent producing symmetri-
cal peaks. Parameters such as solvent polarity, time for analyte
desorption and extraction time were evaluated. During the val-
idation process, the developed method presented speciﬁcity,
linearity (R2 > 0.99), precision (RSD< 15%) and limits of
quantiﬁcation (LOQ) of 30 and 1.37 pg/mL, when liquid and
thermal desorption were employed, respectively.
This simple and highly sensitive method (Fernandes et al.,
2007) compared with methods previously published for analy-
sis of ﬂuoxetine in plasma samples showed to be adequate for
the measurement of ﬂuoxetine in typical and trace concentra-
tion levels (Table 3).
Lanc¸as et al. Fernandes et al. (2007) study demonstrated
that he coupling of SBSE with GC–MS is an appropriate tech-
nique for ﬂuoxetine determination in plasma samples. The re-
ported method had many practical advantages over other
methods described in the literature (Vlase et al., 2005; Juan
et al., 2005; Sabbiono et al., 2004; Fernandes et al., 2006; Rag-
gi et al., 1999; Zarghi et al., 2001; Llerena et al., 2003; Atta-
Politou et al., 2004; Kristoffersen et al., 1999; Molander
et al., 2002; Li et al., 2004; Souverain et al., 2003; Santos-Neto
et al., 2006; Salgado-Petinal et al., 2005), including: simplicity
of the extraction method, small sample volume (1.0 mL), sol-
ventless (utilization of a negligible amount of solvent in the
case of liquid desorption and speciﬁcity due to the use of
MS detection, and high sensitivity. The derivatization tech-
nique using ethyl chloroformate could be easily performed
in situ and permits symmetrical peaks. The developed method
using liquid desorption showed linearity over the range of 1-e in plasma samples.
Detection
mode
LOQ
(pg mL1)
LOD
(pg mL1)
References
tal
Fluorescence 2.5 1.0 Raggi et al. (1999)
UV 10.0 3.0 Zarghi et al. (2001)
UV 4.3 3.1 Llerena et al. (2003)
Fluorescence 8.0 2.5 Atta-Politou et al. (2004)
Fluorescence 1.0 0.4 Vlase et al. (2005)
Fluorescence 30.9 n.a. Kristoﬀersen et al. (1999)
UV 30.9 9.3 Molander et al. (2002)
UV 30.0 15.0 Sabbiono et al. (2004)
UV 3.1 3.1 Li et al. (2004)
MS 5.0 0.5 Juan et al., 2005
MS 25.0 n.a. Souverain et al., 2003
UV 20.0 n.a. Santos-Neto et al. (2006)
MS 1.0 0.25 Salgado-Petinal et al. (2005)
UV 25.0 10.0 Fernandes et al. (2007)
MS 10.0 3.0 Fernandes et al. (2006)
Figure 5 Comparison between LC areas peaks of analytes
extracted by PDMS/PPY and commercial PDMS phase, SBSE
conditions: plasma samples spiked with antidepressants at con-
centrations of 500 ng/mL1 and diluted with borate buffer
solution pH 9.0, time: 40 min, and temperature: 40 C. Desorption
procedure: 200 lL mobile phase, time: 15 min, under sonication.
2
2
Figure 6 Chemical structures of some antiepileptic drugs.
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and LOD of 30.0 and 10.0 pg/mL, respectively.
Thermal desorption also demonstrated precision
(RSD< 12%), and LOQ and LOD of 1.37 and 0.46 pg/
mL, respectively. The LOD and LOQ (in the order of pg/
mL) obtained by Lanc¸as et al. method (Fernandes et al.,
2007) showed better detectability when compared with meth-
ods described in previously published studies (Vlase et al.,
2005; Juan et al., 2005; Sabbiono et al., 2004; Fernandes
et al., 2006; Raggi et al., 1999; Zarghi et al., 2001; Llerena
et al., 2003; Atta-Politou et al., 2004; Kristoffersen et al.,
1999; Molander et al., 2002; Li et al., 2004; Souverain et al.,
2003; Santos-Neto et al., 2006; Salgado-Petinal et al., 2005)
for analysis of ﬂuoxetine in plasma samples. Although thermalTable 4 Comparison of linearity, limit of quantiﬁcation and recover
liquid extraction followed by HPLC-UV analysis in plasma samples
Linearity SBSE/LLE (lg mL1) Linear regression
SBSE vs. LLE
LOQ (lg mL
Phenobarbital y= 0.1372x  0.0117
0.999
(0.08–40) vs.(0.05–40) y = 0.00109x + 0.03189 0.08/0.06
0.998
Carbamazepine y= 0.3159x  0.1157
0.999
(0.08–40) vs. (0.05–40) y = 0.00148x + 0.105 0.08/0.06
0.999
CBZ-E y= 0.2014x  0.0366
0.999
(0.08–40) vs. (0.05–40) y= 0.00107x+ 0.04896 0.08/0.06
0.999
Phenytoin y= 0.0.0423x  0.0104
0.999 0.125/0.08
(0.125–40) vs. (0.09–40) y= 0.00078x+ 0.01877
0.999desorption had demonstrated to produce higher sensitivity to
analyze ﬂuoxetine in typical concentration ranges (80-300 ng/
mL) in plasma samples. Furthermore, the higher sensitivity ob-
tained with thermal desorption makes this method appropriate
for the measurement of ﬂuoxetine at ultra trace level.
5.3. SBSE/LC–UV methods for analysis of antiepileptic drugs in
plasma
Several methods have been published for the determination of
one or more antiepileptic drugs in biological ﬂuids for thera-
peutic drug monitoring (TDM) or for toxicology purposes.
There are various high-performance liquid chromatography
(HPLC) methods for the simultaneous determination of phe-
nytoin (PHT), phenobarbital (PHB), CBZ and their metabo-
lites (Van Rooven et al., 2002; Yoshida et al., 2006; Wahl
et al., 2002; Patil and Bodhankar, 2005; Liu et al., 1993;
Romanyshyn et al., 1994; Kishore et al., 2003; Levert et al.,
2002; Kouno et al., 1993). Recently, Queiroz et al. (2008) de-y of antiepileptic drugs by stir bar sorptive extraction vs. liquid–
.
1) SBSE vs. LLE Recovery SBSE vs. LLE
Concentration (lg mL1) Results (%) (n= 5)
20 78.2 vs. 89.1
8 72.0 vs. 90.0
0.5 76.0 vs. 88.3
20 86.7 vs. 95.3
8 86.9 vs. 95.2
0.5 86.2 vs. 93.1
20 80.3 vs. 90.3
8 81.6 vs. 91.0
0.5 84.9 vs. 91.3
20 62.9 vs. 76.8
8 65.6 vs. 76.3
0.5 63.3 vs. 78.6
32 M.G. Kassemscribed a stir bar sorptive extraction and high-performance li-
quid chromatography–UV detection (SBSE/HPLC-UV) meth-
od for therapeutic drug monitoring (TDM) of antiepileptic
drugs (carbamazepine, carbamazepine 10,11-epoxide, phenyt-
oin and phenobarbital) (Fig. 6) in plasma samples and com-
pared with a liquid–liquid extraction (LLE/HPLC-UV)
method.
Important factors in optimization of SBSE efﬁciency such
as pH, extraction time and desorption conditions (solvents,
mode magnetic stir, mode ultrasonic stir, time and number
of steps) assured recoveries ranging from 72% to 86%, exceptTable 5 Comparison of intra- and inter-day precisio
bar sorptive extraction vs. liquid:liquid extraction fol
Drugs (lg mL1) Precision intra-assay
CV (%) n= 10;
SBSE vs. LLE
Phenobarbital
20 6.3 vs. 3.5
4 5.2 vs. 4.5
1 7.6 vs. 7.8
Carbamazepine
20 3.7 vs. 5.4
4 6.8 vs. 5.2
1 8.8 vs. 6.3
CBZ-E
20 6.4 vs. 4.2
4 7.7 vs. 6.2
1 8.5 vs. 5.8
Phenytoin
20 5.9 vs. 3.6
4 5.9 vs. 6.6
1 8.3 vs. 9.7
CV, coefﬁcient of variation; LLE, liquid:liquid extractio
Figure 7 (A) Chromatogram obtained from a blank (without intern
with 0 lg/mL. (1) Phenobarbital, (2) carbamazepine-10,11-poxide, (3)
and (5) carbamazepine.for phenytoin (62%). Separation was obtained using a reverse
phase C18 column with UV detection (210 nm). The mobile
phase composed of water–acetonitrile (78:22, v/v).
The SBSE/HPLC–UV method was linear over a working
range of 0.08-40.0 lg/mL for phenytoin (Table 4).
The intra-assay and inter-assay precision and accuracy
(Table 5) were studied at three concentrations (1.0, 4.0 and
20.0 lg/mL). The intra-assay coefﬁcients of variation (CVs)
for all compounds were less than 8.8% and all inter-CVs were
less than 10%. The speciﬁcity (selectivity) of the reported
method (Queiroz et al., 2008) is demonstrated by representa-n and accuracy of the antiepileptic drugs by stir
lowed by HPLC-UV analysis in plasma samples.
Precision inter-assay
CV (%) n= 5;
SBSE vs. LLE
Accuracy error
(%); SBSE vs. LLE
6.5 vs. 7.7 6.4 vs. 4.2
6.8 vs. 6.6 6.0 vs. 3.5
6.3 vs. 5.8 8.2 vs. 8.2
7.8 vs. 6.9 4.3 vs. 3.3
9.5 vs. 8.9 3.7 vs. 5.2
9.0 vs. 9.6 9.2 vs. 8.6
9.5 vs. 8.9 9.2 vs. 8.5
7.1 vs. 8.8 8.6 vs. 9.1
8.4 vs. 7.8 9.2 vs. 8.9
7.2 vs. 9.8 9.3 vs. 8.5
5.0 vs. 5.9 6.5 vs. 8.2
9.7 vs. 8.3 9.4 vs. 9.6
n; SBSE, stir bar sorptive extraction.
al standard) and (B) chromatogram obtained from plasma spiked
internal standard (5-ethyl-5-p-tolylbarbituric acid), (4) phenytoin
Stir bar sorptive extraction for central nervous system drugs from biological ﬂuids 33tive chromatograms from drug-free human plasma sample,
and the same sample spiked with antiepileptic drugs in thera-
peutic interval concentrations (Fig. 7A and B), which showed
the ability of the method to measure the drugs unequivocally
in the presence of endogenous plasma components. Additional
drug-free human plasma samples from several individuals were
tested and showed no signiﬁcant interference at the retention
times of the analytes.
Limits of quantiﬁcation were 0.08 lg/mL for carbamaze-
pine, carbamazepine-10,11-epoxide and phenobarbital and
0.125 lg/mL for phenytoin. No interference of drugs normally
associated with antiepileptic drugs such as primidone, lamotri-
gine, zonizamide, haloperidol, chlorpromazine, risperidone,
moclobemide and several benzodiazepines and also for methyl-
dopa, captopril, furosemide, hydrochlorothiazide, methoclo-
pramide, acetaminophen, caffeine, salicylic acid, diclophenac,
indomethacin, sulphamethoxazole, metoprolol, propranolol,
amiodarone, cimetidine, ranitidine and prednisone, were
observed.N
N N
N
O
CH3O
H3C
CH3
Caffeine
log P = 0.1
N
N N
N
O
CH3O
H3C
1,7-Dimethylxanthine
log P = N.A.
N
N N
N
O
O
H3C
1-Methylxanthine
log P = − 0.3
N
N N
N
O
O
H3C
1-Methyluric acid
log P = − 0.6
O
Figure 8 Chemical structure of caffeine and three of its
metabolites.
Figure 9 HPLC RAM–SBSE sample chromatograph for (a) plasma
mL caffeine.Based on ﬁgures of merit results, the SBSE/HPLC-UV
technique, (Queiroz et al., 2008), proved adequate data for
antiepileptic drugs analyses from therapeutic levels. This meth-
od was successfully applied to the analysis of real samples and
was as effective as the LLE/HPLC method.
5.4. Analysis of caffeine and its metabolites in biological ﬂuids
Stir bar sorptive extraction based on restricted access material
(RAM) for the direct extraction of caffeine and its metabolites
(Fig. 8) in biological ﬂuids was reported by Lambert et al.
(2005). Restricted access materials (RAM) are a class of bio-
compatible absorbent particles enabling the direct extraction
of analytes from biological ﬂuid (e.g. plasma and urine)
(Souverain et al., 2004).
In particular, alkyl-diol silica (ADS) RAM particles are
able to fractionate a sample into the protein matrix and the
analytes with a controlled pore size that acts are physical bar-
rier to exclude macromolecules (15,000 molecular weight).
Simultaneously with the size exclusion process, low molecular
weight compounds are extracted and enriched via-partition,
into the phase’s interior (Mullett and Pawliszyn, 2002). Vari-
ous extraction cartlages, such as C4, C8, C18 and ion exchange
(Rbeida et al., 2004, 2003) are available to provide a wide
range of selectivity. The exterior of the silica based particles
have been modiﬁed with diol moieties to prevent irreversible
adsorption of protein and hence acts as a biocompatible sur-
face, enabling direct exposure to biological ﬂuids.
To extend the effectiveness and robustness of SBSE ap-
proach to biological ﬂuids, a glass stir bar enclosing a magnet
was coated with RAM particles. The novel RAM SBSE device
could be directly stirred in biological ﬂuids for analyte extrac-
tion without fouling of the coating from proteins. Its ability to
directly extracted caffeine and various metabolites from plas-
ma, followed by liquid desorption and HPLC-UV analysis
was studied. In contrast to existing methods for caffeine anal-
ysis in biological ﬂuids such as liquid–liquid extraction (Krul
and Hageman, 1998; Bendriss et al., 2000) solid-phase extrac-
tion (SPE) (Zydron et al., 2004; Caubet et al., 2002; Baud-
Camus et al., 2001; Georga et al., 2001) and solid-phase mic-/10% methanol and (b) plasma/10% methanol spiked with 25 lg/
34 M.G. Kassemroextraction (Kumazawa et al., 1999), the main advantage of
the novel RAM-SBSE extraction was the ability to perform di-
rect extractions, minimizing long and complicated sample
preparation procedures. It was observed that this novel
RAM-SBSE device enabled caffeine and selected metabolites
to be extracted from spiked plasma with minimum sample
preparation (Lambert et al., 2005).
A biocompatible stir bar sorptive extraction (SBSE) device
was prepared by Lambert et al. (2005) using an alkyl-diol silica
(ADS) restricted access material (RAM) as the SBSE coating.
The RAM-SBSE bar was able to simultaneously fractionate
the protein component from a biological sample, while directly
extracting caffeine and its metabolites, overcoming the present
disadvantages of direct sampling in biological matrices by
SBSE, such as fouling of the extraction coating by proteins.
Desorption of the analytes was performed by stirring the
bar in a water/ACN mixture (3/1, v/v) and subsequently recon-
centrating the sample solution in water to enable HPLC–UV
analysis to be performed. The limit of detection, based on a
signal to noise ratio of 3, for caffeine was 25 ng/mL in plasma.
The method was conﬁrmed to be linear over the range of 0.5-
100 lg/mL of caffeine with an average linear coefﬁcient (R3)
value of 0.9981.
The injection repeatability and intra-assay precision of the
method were evaluated over 10 injections, resulting in a %
RSD of 8%. Caffeine recovery was also discussed as follows:
after performing RAM–SBSE with caffeine spiked rat plasma,
it was observed that extraction produced a lower recovery of
caffeine relative to caffeine standards in PBS. One possibility
for lower recoveries in plasma is the high protein binding of
caffeine with plasma protein (Lucas et al., 2003), which would
prevent the absorption of caffeine in the C18 phase of the
RAM-SBSE bar. To prevent this phenomenon, 10% v/v of
methanol was added to each sample prior to sample extraction
to help disrupt any protein binding.
The small addition of methanol did not cause any observa-
ble precipitation of the biological material but did ensure a full
recovery in plasma. Blank extractions from plasma were per-
formed to make sure that no interference from the biological
matrix extracted by the RAM-SBSE bar co-eluted. Fig. 9
shows a typical chromatogram of caffeine extraction from
blank and spiked plasma using the RAM–SBSE device.
The absence of chromatographic peaks at the elution time
for caffeine in the blank plasma sample conﬁrmed the absence
of any interference being co-extracted and eluted with caffeine.
The impact of plasma dilution was also tested by performing
RAM-SBSE extraction from whole plasma (containing 10%
methanol, v/v) spiked with 10 lg/mL caffeine. No signiﬁcant
difference in the recovery was observed and no additional ma-
trix components were detected in the HPLC chromatogram,
conﬁrming the ability of the RAM–SBSE device to provide a
very clean extract in this complex bioﬂuid.
The RAM-SBSE device was robust to withstand the fric-
tional forces associated with stir rig at high RPM and could
be re- used for over 50 times extraction in plasma without
signiﬁcant loss in extraction efﬁciency (Lambert et al.,
2005) and simple use, providing many direct extraction and
subsequent determination of caffeine and its metabolites in
biological ﬂuids. In contrast to existing sample preparation
methods (Krul and Hageman, 1998; Bendriss et al., 2000;
Baud-Camus et al., 2001; Georga et al., 2001) for the analysis
of caffeine and selected metabolites in biological ﬂuids, thisfeasibility study using a biocompatible SBSE approach was
advantageous in terms of simplifying the sample preparation
procedures.6. Conclusion
In the present review, several aspects of SBSE are reviewed,
including the basic theory, experimental parameters optimiza-
tions, applications (specially for central nervous system drugs),
and limitations. As well-known limitation of this technique is
the fact that only one sorbent (PMDS) is commercially avail-
able until this manuscript was written. This limits the applica-
tion of this technique to the analysis of non-polar and some
intermediate polarity compounds, requiring other steps such
as derivatization for the analysis of the more polar ones.
On the other hand, in-house polar phases have been suc-
cessfully used with SBSE, being presented and described in this
review. New approaches such as RSE, based upon SBSE con-
cepts introduced. Considering its applications in biological
analysis, described in this review, joined with developments
of new sorbents, interfaces, and analytical approaches, it can
be concluded that SBSE certainly will occupy an important
role as a major sample preparation micro technique in the near
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